KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Minority Interest (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 9 years of Minority Interest data on record, last reported at $77.3 million in Q4 2025.

  • For Q4 2025, Minority Interest rose 18.96% year-over-year to $77.3 million; the TTM value through Dec 2025 reached $77.3 million, up 18.96%, while the annual FY2025 figure was $77.3 million, 18.96% up from the prior year.
  • Minority Interest reached $77.3 million in Q4 2025 per AMRX's latest filing, up from $67.8 million in the prior quarter.
  • Across five years, Minority Interest topped out at $77.3 million in Q4 2025 and bottomed at $13.1 million in Q1 2021.
  • Average Minority Interest over 5 years is $39.4 million, with a median of $34.6 million recorded in 2023.
  • Peak YoY movement for Minority Interest: rose 4.11% in 2021, then skyrocketed 79.51% in 2023.
  • A 5-year view of Minority Interest shows it stood at $16.9 million in 2021, then skyrocketed by 47.57% to $24.9 million in 2022, then soared by 65.51% to $41.3 million in 2023, then surged by 57.35% to $65.0 million in 2024, then increased by 18.96% to $77.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Minority Interest were $77.3 million in Q4 2025, $67.8 million in Q3 2025, and $65.8 million in Q2 2025.